RTW Biotech Opportunities Ltd - investment fund managed by RTW Investments LP that specialises in life sciences sector - Invests in Boston, Massachusetts-based Aktis Oncology Inc, a clinical-stage developer of novel targeted alpha radiopharmaceuticals to treat a range of solid tumours. Alongside other investment vehicles owned by RTW Investments, RTW Biotech co-led Aktis’s series B funding round, raising $175 million.
Roderick Wong, managing partner & chief information officer at RTW Investments, says: ‘Aktis Oncology’s innovative approach to treating solid tumours demonstrates a significant advancement in cancer therapy. We believe in their mission and are confident that their miniprotein radioconjugate platform and experienced team will bring transformative treatments to patients in need. Our investment underscores our commitment to supporting pioneering companies that are making remarkable strides in oncology.’
Current stock price: $1.51, down 0.2% in London on Wednesday morning
12-month change: up 24%
Copyright 2024 Alliance News Ltd. All Rights Reserved.
